Drug Profile
Insulin intranasal - CPEX Pharmaceuticals
Alternative Names: Intranasal insulin - CPEX; NasulinLatest Information Update: 21 Jan 2022
Price :
$50
*
At a glance
- Originator Bentley Pharmaceuticals
- Developer CPEX Pharmaceuticals
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 18 Mar 2010 Suspended - Phase-II for Type-1 diabetes mellitus in India (Intranasal)
- 18 Mar 2010 Suspended - Phase-II for Type-1 diabetes mellitus in USA (Intranasal)
- 18 Mar 2010 Suspended - Phase-II for Type-2 diabetes mellitus in India (Intranasal)